Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Anna R. Blankstein, Neelan Sriranjan, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 6092–6093.

https://doi.org/10.1182/blood-2022-170961

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Neelan Sriranjan, Anna R. Blankstein, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11632–11633.

https://doi.org/10.1182/blood-2022-171047

Published: 2022

Journal Articles

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Anna R. Blankstein, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Emily Rimmer, Donald S. Houston, Sylvain Lother, Asher Mendelson, Allan Garland, Ryan Zarychanski, Annette E. Hay, Rena Buckstein, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11656–11657.

https://doi.org/10.1182/blood-2022-164450

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12317–12318.

https://doi.org/10.1182/blood-2022-170652

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12315–12316.

https://doi.org/10.1182/blood-2022-170553

Published: 2022

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Characteristics of Hepatic Veno-Occlusive Disease from the Cell Therapy Transplant Canada Registry: A Retrospective Observational Study

Kevin Brown, MD BA, Kristjan Paulson, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-142237

Published: 2020

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Dennis Dong Hwan Kim, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2019) 134 (Supplement_1): 1644.

https://doi.org/10.1182/blood-2019-128283

Published: 2019

Journal Articles

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Dennis Dong Hwan Kim, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, Stephen Couban, MDBSc, Robert Delage, MD, Anargyros Xenocostas, MD, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2018) 132 (Supplement 1): 787.

https://doi.org/10.1182/blood-2018-99-114656

Published: 2018

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Intergraft Variability in Nonhematopoietic Immunoregulatory Cell Number and Expression of Immune Checkpoint Inhibitor Receptors and Ligands in Both Allo- and Autografts: Potential Target for Intervention

Qingdong Guan, MD PhD, Scott Gilpin, James Doerksen, Lauren Bath, Tracey Lam, Kristjan Paulson, FRCPC, Pascal Lambert, Yun Li, Donna A. Wall, MD

Blood (2016) 128 (22): 3382.

https://doi.org/10.1182/blood.V128.22.3382.3382

Published: 2016

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Kristjan Paulson, MD, Ruta Brazauskas, PhD, Naya He, MPH, David Szwajcer, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Yoshiko Atsuta, MD PhD, Jignesh D Dalal, MD, Theresa Hahn, PhD, Carmem Bonfim, MD, Nandita Khera, MD, Linda J. Burns, MD, Lih-Wen Mau, PhD MPH, Navneet S. Majhail, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 842.

https://doi.org/10.1182/blood.V128.22.842.842

Published: 2016

Journal Articles

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

Craig Speziali, MD MSc, FRCPC, Andrew Daly, MD FRCPC, Mohamed Abuhaleeqa, MD, Janet Nitta, Yasser Abou Mourad, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kristjan Paulson, MD FRCPC

Blood (2016) 128 (22): 663.

https://doi.org/10.1182/blood.V128.22.663.663

Published: 2016

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Daniel J. DeAngelo, MD PhD, Kristen Stevenson, MS, Donna S Neuberg, ScD, Lewis B. Silverman, MD, Karen K. Ballen, MD, Julie D. Asch, MD, Yasser Abou Mourad, MD, Kristjan Paulson, MD FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP, David Avigan, MD, Julie Bergeron, MD, Stephen Couban, MD, William Blum, MD, John Storring, MD, Martha Wadleigh, MD, David P. Steensma, MD, Jeffrey Supko, PhD, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2015) 126 (23): 80.

https://doi.org/10.1182/blood.V126.23.80.80

Published: 2015

NARROW

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Characteristics of Hepatic Veno-Occlusive Disease from the Cell Therapy Transplant Canada Registry: A Retrospective Observational Study

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Provincial Disparities in Access to Allogeneic Transplant in Canada

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Intergraft Variability in Nonhematopoietic Immunoregulatory Cell Number and Expression of Immune Checkpoint Inhibitor Receptors and Ligands in Both Allo- and Autografts: Potential Target for Intervention

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only